ASRGL1 Knockout TE1 Polyclonal Cells comprise a polyclonal knockout cell population generated by CRISPR/Cas9-mediated disruption of the ASRGL1 gene in the human TE1 esophageal squamous cell carcinoma line. This product provides researchers with a robust loss-of-function model to investigate ASRGL1 function in a cancer-relevant epithelial background, without relying on single-cell clone isolation.
The TE1 cell line, established from a human esophageal squamous cell carcinoma, retains key features of malignant epithelial cells, including aberrant proliferation and altered metabolic profiles. As a widely utilized model in esophageal cancer biology, TE1 cells are particularly suited for dissecting the interplay between amino acid metabolism, signal transduction, and therapeutic sensitivity.
ASRGL1 encodes L-asparaginase, which hydrolyzes L-asparagine to L-aspartate and ammonia, thereby modulating intracellular asparagine pools. This enzymatic activity is regulated transcriptionally by ATF4 and p53 and silenced by DNA methylation in certain cancers. Through its control of asparagine levels, ASRGL1 acts upstream of ASNS and mTORC1, affecting downstream targets such as S6K and eIF4E, which orchestrate protein synthesis. Low asparagine suppresses mTORC1, leading to reduced translation and enhanced apoptosis via BCL2 family members. ASRGL1 itself forms homodimers for catalytic activity, positioning it as a critical gatekeeper between asparagine metabolism and cell fate determination.
In esophageal squamous cell carcinoma, ASRGL1 knockout in TE1 cells creates a powerful system to study amino acid deprivation responses and apoptotic priming. This model is instrumental for exploring how cancer cells adapt to nutrient stress and for identifying metabolic vulnerabilities that could be exploited therapeutically. It enables assessment of mTORC1 signaling dynamics, ASNS upregulation, and crosstalk with pro-survival factors, all of which contribute to drug resistance and tumor progression.
Typical experimental applications include western blotting to confirm ASRGL1 ablation, asparaginase activity measurements to verify enzymatic loss, and cell viability assays under asparagine-free conditions to evaluate metabolic addiction. Apoptosis induction can be quantified by Annexin V/PI staining, while RT-qPCR monitors ASNS transcript levels as a downstream responder. Metabolomic profiling via LC-MS captures changes in aspartate and asparagine, and RNA-seq reveals transcriptome-wide reprogramming. Flow cytometry permits cell cycle analysis to link ASRGL1 status to proliferation control. These assays collectively enable in-depth functional annotation of ASRGL1 in cancer biology. For further information, please reach out to Ascent Research.
